Pfizer (PFE) Equity Ratio (2009 - 2026)

Pfizer (PFE) has 18 years of Equity Ratio data on file, last reported at 0.43 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.43, down 0.58% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.43 (down 0.58% YoY), and the FY2025 annual result was 0.42, changed 0.17% from the prior year.
• Equity Ratio rose to 0.43 in Q1 2026 per PFE's latest filing, from 0.42 in the prior quarter.
• Over five years, Equity Ratio peaked at 2.26 in Q4 2022 and troughed at 0.39 in Q4 2023.
• A 5-year average of 0.55 and a median of 0.44 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio surged 190.76% in 2022, then plunged 79.98% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.49 in 2022, then slipped by 19.03% to 0.39 in 2023, then advanced by 5.2% to 0.41 in 2024, then advanced by 0.17% to 0.42 in 2025, then climbed by 4.27% to 0.43 in 2026.
• Business Quant data shows PFE's Equity Ratio at 0.43 in Q1 2026, 0.42 in Q4 2025, and 0.45 in Q3 2025.